## RARE: Ultragenyx Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -27.6% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($18.67)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 1, Bearish: 1)

**1. StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures**
- Source: Genetic Engineering and Biotechnology News | 20260104T190913 | Bearish | Relevance: 100%
- Ultragenyx Pharmaceutical and Mereo BioPharma saw their shares drop significantly after their brittle bone disease candidate, setrusumab, failed to meet primary endpoints in late-phase clinical trials. While the drug showed improvements in bone mineral density, it did not significantly reduce the annualized clinical fracture rate. Both companies announced plans for expense reductions and are evaluating the future of their programs.

**2. Ultragenyx granted FDA priority review for gene therapy in rare brain disorder**
- Source: MSN | 20260103T190908 | Bullish | Relevance: 100%
- Ultragenyx Pharmaceutical has been granted priority review by the FDA for its gene therapy, GTX-102, designed to treat Angelman syndrome. The FDA's decision is based on positive data from a Phase 1/2 study, which demonstrated clinical improvements in patients with this rare and severe neurodevelopmental disorder. This priority review designation anticipates an accelerated review timeline for the therapy.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-0.8%)
- JPMORGAN CHASE & CO: 8.3% (+146.0%)
- FMR, LLC: 7.6% (+179.6%)
- Blackrock Inc.: 6.7% (+2.7%)
- Sands Capital Manage: 3.9% (-4.4%)

### Key Risks

1. Elevated short interest (9.2%): bears positioning against stock.
2. Long-term trend broken: trading 30.1% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Revenue growth strong at 20% YoY. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.2B |
| Beta | 0.15 |
| 52W Range | $18.41 - $46.50 |
| Short Interest | 9.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.24 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -42.6% to -27.6% (+15.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 31.6pp (needs >4.0% for momentum thesis). MRS_5 turning positive (2.8%) - potential reversal signal. AM_20 at -27.5% indicates price below own 20MA trend. Underperforming sector by 28.1pp, stock-specific weakness. Below SMA200 (0.70x), long-term trend not supportive. MACD histogram bearish (-1.39), momentum weakening. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -27.60% (CS: 50) | Weak |
| RSI_14 | 30.5 | Neutral |
| MACD Histogram | -1.39 | Bearish |
| vs SMA20 | 0.725x | Below |
| vs SMA50 | 0.705x | Below |
| vs SMA200 | 0.699x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $23.11
- **Stop Loss:** $18.67 (19.2% risk)
- **Target:** $27.55 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 194
- **Position Value:** $4,483.34
- **Portfolio %:** 4.48%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-12 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.21 | $-1.81 | -49.7% |
| 2025Q2 | $-1.32 | $-1.17 | +11.4% |
| 2025Q1 | $-1.64 | $-1.57 | +4.4% |
| 2024Q4 | $-1.27 | $-1.39 | -9.4% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*